Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis ointment shows promise in large chinese trial

NCT ID NCT05919082

Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new ointment (LEO 90100) against a standard one (Daivobet) for stable plaque psoriasis in 604 Chinese adults. Participants applied the treatment for 4 weeks. The goal was to see if the new ointment could clear or nearly clear psoriasis patches better than the standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

604 people

The number who actually took part.

Started

Jun 2023

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chinese native * Aged 18 or over * A clinical diagnosis of stable plaque psoriasis for at least 6 months * Stable plaque psoriasis on the trunk and/or limbs (excluding psoriasis on the face, scalp, genitals, and skin folds) involving 2-30% of the body surface at Day 1 (Visit 2) of the trial. * Having a Physician Global Assessment of at least 'mild' at Day 1 (Visit 2) * An mPASI score of at least 2 on the trunk and/or limbs at Day 1 (Visit 2) * Women of childbearing potential must use an adequate form of birth control throughout the trial and for at least 8 weeks after last administration of IMP * Male subjects with a female partner of childbearing potential must use adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) * Having a signed and dated informed consent. Exclusion Criteria: * Systemic use of biological treatments with a potential effect on psoriasis vulgaris within the specified time periods prior to treatment assignment (depending on treatment) * Systemic treatments with all therapies other than biological treatments with a potential effect on psoriasis vulgaris within 4 weeks prior to treatment assignment * Psoralen combined with ultraviolet A therapy (PUVA) within 4 weeks prior to treatment assignment * Systemic treatment with Apremilast within 4 weeks prior to treatment assignment * Ultraviolet B (UVB) therapy within 2 weeks prior to treatment assignment * Topical treatment of psoriasis with strong corticosteroids within 2 weeks prior to treatment assignment * Topical treatment of psoriasis with traditional Chinese medicine within 2 weeks prior to treatment assignment * Treatment with any non-marketed drug substance (any agent which has not yet been made available for clinical use) within 4 weeks/5 half-lives prior to treatment assignment * Any other topical treatment that could affect plaque psoriasis within 2 weeks prior to treatment assignment * Current diagnosis of guttate, erythrodermic, exfoliative, pustular or unstable psoriasis * Patients with any of the following conditions present on any skin area: viral lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, acne rosacea, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers and wounds * Disorders of calcium metabolism * Renal insufficiency, hepatic disorders or severe heart disease * Cushing's disease or Addison's disease * Known or suspected hypersensitivity to any component(s) of the investigational medicinal product (IMP) * Current participation in any other interventional clinical trial * Previously screened in this trial * Participation in another clinical trial within 4 weeks prior to treatment assignment * Women who are pregnant, wishing to become pregnant or are breast-feeding * Chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance * Employees of the trial site or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stable plaque psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stable plaque psoriasis

Contacts and locations

Locations

  • LEO Pharma Investigational Site

    Bengbu, Anhui, 233060, China

  • LEO Pharma Investigational Site

    Hefei, Anhui, 230022, China

  • LEO Pharma Investigational Site

    Beijing, Beijing Municipality, 100044, China

  • LEO Pharma Investigational Site

    Beijing, Beijing Municipality, 100050, China

  • LEO Pharma Investigational Site

    Chongqing, Chongqing Municipality, 400021, China

  • LEO Pharma Investigational Site

    Chongqing, Chongqing Municipality, 400042, China

  • LEO Pharma Investigational Site

    Guangzhou, Guangdong, 510080, China

  • LEO Pharma Investigational Site

    Guangzhou, Guangdong, 516006, China

  • LEO Pharma Investigational Site

    Shenzhen, Guangdong, 518020, China

  • LEO Pharma Investigational Site

    Cangzhou, Hebei, 061000, China

  • LEO Pharma Investigational Site

    Chengde, Hebei, 067000, China

  • LEO Pharma Investigational Site

    Shijiangzhuang, Hebei, 050030, China

  • LEO Pharma Investigational Site

    Nanyang, Henan, 473004, China

  • LEO Pharma Investigational Site

    Shiyan, Hubei, 442000, China

  • LEO Pharma Investigational Site

    Wuhan, Hubei, 430022, China

  • LEO Pharma Investigational Site

    Changsha, Hunan, 410011, China

  • LEO Pharma Investigational Site

    Baotou, Inner Mongolia, 014010, China

  • LEO Pharma Investigational Site

    Baotou, Inner Mongolia, 014016, China

  • LEO Pharma Investigational Site

    Hohhot, Inner Mongolia, 010000, China

  • LEO Pharma Investigational Site

    Wuxi, Jiangsu, 214002, China

  • LEO Pharma Investigational Site

    Yangzhou, Jiangsu, 225003, China

  • LEO Pharma Investigational Site

    Zhenjiang, Jiangsu, 212001, China

  • LEO Pharma Investigational Site

    Changchun, Jilin, 130021, China

  • LEO Pharma Investigational Site

    Xi'an, Shaanxi, 510080, China

  • LEO Pharma Investigational Site

    Dongying, Shandong, 257099, China

  • LEO Pharma Investigational Site

    Jinan, Shandong, 250013, China

  • LEO Pharma Investigational Site

    Jinan, Shandong, 250022, China

  • LEO Pharma Investigational Site

    Shanghai, Shanghai Municipality, 200443, China

  • LEO Pharma Investigational Site

    Chengdu, Sichuan, 610044, China

  • LEO Pharma Investigational Site

    Suining, Sichuan, 629000, China

  • LEO Pharma Investigational Site

    Hangzhou, Zhejiang, 310003, China

  • LEO Pharma Investigational Site

    Hangzhou, Zhejiang, 310009, China

  • LEO Pharma Investigational Site

    Hangzhou, Zhejiang, 310014, China

  • LEO Pharma Investigational Site

    Hangzhou, Zhejiang, 310016, China

  • LEO Pharma Investigational Site

    Jiaxing, Zhejiang, 314001, China

  • LEO Pharma Investigational Site

    Ningbo, Zhejiang, 315010, China

  • LEO Pharma Investigational Site

    Ningbo, Zhejiang, 315016, China

  • LEO Pharma Investigational Site

    Wenzhou, Zhejiang, 325000, China